Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
106.15
-0.23 (-0.22%)
At close: Apr 24, 2025, 4:00 PM
102.52
-3.63 (-3.42%)
After-hours: Apr 24, 2025, 6:03 PM EDT
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.67B in the quarter ending March 31, 2025, a decrease of -0.28%. This brings the company's revenue in the last twelve months to $28.74B, up 4.68% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.74B
Revenue Growth
+4.68%
P/S Ratio
4.61
Revenue / Employee
$1,632,670
Employees
17,600
Market Cap
132.33B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
GILD News
- 4 hours ago - Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 8 hours ago - Gilead reports quarterly profit, revenue flat as cancer sales slow - Reuters
- 8 hours ago - Gilead Sciences Announces First Quarter 2025 Financial Results - Business Wire
- 3 days ago - Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type - Reuters
- 3 days ago - Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer - Business Wire
- 14 days ago - Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 - Business Wire
- 20 days ago - Top 3 Nasdaq 100 stocks rising as it moves into a correction - Invezz
- 23 days ago - Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks - CNBC